The present disclosure provides compositions and methods related to aptamers and aptamer-based sensors. In particular, the present disclosure provides methods to discover high-affinity aptamers with slow off-rate binding kinetics as well as aptamer-based sensors, and related detection assays, that are capable of detecting a target analyte (and derivatives and analogs thereof) at clinically relevant concentrations in biological fluids in a manner that is rapid, specific, and sensitive.
Provided herein are compounds (e.g., polymers) that include a polymer backbone comprising one or more hydrophobic unit(s) and one or more hydrophilic unit(s) and one or more dye(s) and/or biomolecule(s) attached to a hydrophobic unit and/or hydrophilic unit. Compositions including such compounds, methods of making such compounds, and methods of using such compounds are also provided.
A system, method, and device for retaining an implanted medical device is disclosed, the device including: a sleeve body extending circumferentially around a first longitudinal axis. The sleeve body defines a first aperture on a first end of the sleeve body and a second aperture on a second end of the sleeve body. The second end is spaced apart longitudinally from the first end of the sleeve body. The device further includes a sheath coupled to an inner surface of the sleeve body and extending circumferentially around a second longitudinal axis. The sheath defines a third aperture on a first end of the sheath and a fourth aperture on a second end of the sheath. The second end of the sheath is spaced apart from the first end of the sheath.
Disclosed herein is a method for accelerating aging of a beverage, the method comprising exposing the beverage to wood in a water bath at a temperature from 125°F-141°F for 14 to 28 days. Also disclosed is a kit for accelerating aging of a beverage, wherein the kit comprises wood designed for flavoring beverages and a kettle comprising a water bath. Further disclosed is an alcoholic beverage, wherein said beverage has been aged for less than 60 days, and wherein said beverage has a concentration of isoamyl alcohol of less than 200,000 µg/L, a concentration of ethyl decanoate of greater than 2,000 µg/L, and a concentration of syringol between 100 and 1,000 µg/L.
C12G 3/07 - Flavouring with wood extracts, e.g. generated by contact with woodWood pretreatment therefor
C12G 3/08 - Preparation of other alcoholic beverages by methods for altering the composition of fermented solutions or alcoholic beverages not provided for in groups
C12H 1/18 - Pasteurisation, sterilisation, preservation, purification, clarification, or ageing of alcoholic beverages without precipitation by physical means, e.g. irradiation by heating
The present disclosure provides compositions, methods, and systems related to programmable base editing. In particular, the present disclosure provides novel genome modification technology involving introducing a chemical modification (e.g., a replication-blocking lesion) at a specific target site that blocks DNA replication and results in a site-specific nucleotide mutation. The compositions, methods, and systems described herein facilitate efficient site-specific genome modification of a DNA target, while minimizing the unintended edits and cellular toxicity associated with current genome editing approaches.
The present disclosure provides compositions, systems, and methods related to cellular transduction. In particular, the present disclosure provides compositions, systems, and methods for generating a dry scaffold that facilitates rapid and highly efficient cellular transduction.
The subject matter described herein is directed to cross-linked chitosan hydrogels having desired properties and methods for their preparation and use.
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
8.
COMPOSITIONS AND METHODS RELATING TO ENZYMATIC DNA SYNTHESIS
The present disclosure provides compositions and methods related to enzymatic nucleic acid synthesis. In particular, the present disclosure provides novel compositions and methods for generating a plurality of modified nucleic acid oligos using a nucleic acid template molecule.
C12Q 1/6848 - Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
C12Q 1/6853 - Nucleic acid amplification reactions using modified primers or templates
9.
PARALLELING POWER SEMICONDUCTORS WITH DIFFERENT SWITCHING FREQUENCIES
Various examples are provided related to operation of parallel semiconductors with different switching frequencies. In one example, a method of reducing conduction and switching losses in a high current switching circuit includes controlling two hybrid switches to conduct concurrently or alternately, each of the hybrid switches include a wide bandgap device and a silicon power device. Controlling of the silicon power device is at a first gate switching frequency and controlling of the wide bandgap device is at a second gate switching frequency, where the first gate switching frequency is lower than the second gate switching frequency. The silicon power device can be switched at a frequency of about 50 or 60 Hertz. The wide bandgap device can be switched at a frequency greater than 1 kHz.
A cargo container system, comprising: a vehicle with a cargo compartment; a cargo container configured to fit within the cargo compartment; and, a weight balance adjustment mechanism, comprising at least one of a load sensor and a position sensor, configured to adjust the position of the cargo container within the cargo compartment using data received from the at least one of a load sensor and a position sensor.
G01G 19/08 - Weighing apparatus or methods adapted for special purposes not provided for in groups for incorporation in vehicles
G01G 19/10 - Weighing apparatus or methods adapted for special purposes not provided for in groups for incorporation in vehicles having fluid weight-sensitive devices
G01G 19/12 - Weighing apparatus or methods adapted for special purposes not provided for in groups for incorporation in vehicles having electrical weight-sensitive devices
Methods and systems for rapid detection of volatile organic compounds (VOCs) from plants, such as onions and other fruits and vegetables, are described. The systems include one or more colorimetric sensing elements and a cell-damaging component that can damage one or more cells in a plant sample to induce VOC release. In an exemplary system, a colorimetric dye array is combined with one or more needles on a single sensor body. Use of the system for classifying onion bulbs based on tearing intensity and/or pungency is described.
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01N 1/22 - Devices for withdrawing samples in the gaseous state
12.
COMPOSITIONS AND METHODS FOR PURIFYING LENTIVIRUS PARTICLES
The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides peptides, compositions, adsorbents, and related methods, capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from samples during the production and purification of lentivirus particles.
The present disclosure is directed to a multi-variant control system for an industrial facility. In one form of a method, a processor monitors a behavior of a distributed control system with respect to at least a set of uncontrolled variables, a set of controlled variables, and a set of monitored variables; trains a model based on the monitored behavior utilizing at least one of artificial intelligence or machine learning; and identifies, based on the model, a subset of controlled variables for optimization. Further, the processor monitors a behavior of the industrial facility without the use of the distributed control system; optimizes, based on the monitored behavior, the subset of controlled variables to obtain a target result and restrict variation of values of the set of monitored values; and executes a control system for the industrial facility based on the optimization of the subset of controlled variables.
G05B 13/02 - Adaptive control systems, i.e. systems automatically adjusting themselves to have a performance which is optimum according to some preassigned criterion electric
14.
COMPOUNDS INCLUDING A WATER-SOLUBILIZATION MOTIF AND METHODS OF USE THEREOF
Described herein are compounds that include a tetrapyrrole macrocycle and a water solubilizing group that is attached to the tetrapyrrole macrocycle along with methods of using the same.
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
15.
TOBACCO PLANTS WITH REDUCED NICOTINIC ALKALOID LEVELS
The present disclosure provides compositions and methods related to tobacco plants. In particular, the present disclosure provides novel methods for producing tobacco plants, and any related tobacco products, having low nicotinic alkaloid content. Tobacco plants produced according to the methods of the present disclosure exhibit reduced levels of nicotinic alkaloids (e.g., nicotine) compared to both naturally-occurring and transgenic tobacco plants, and thus represent a commercially valuable alternative to currently available tobacco varieties.
An exemplary left ventricular assist device (LVAD) and method that employs design and material designs to reduce the thrombosis risk of LVAD implant in a patient. One feature of the design includes a stented inlet member for the device that can reduce or fully eliminate a flow stasis that can trigger blood protein adsorption that can lead to chain reactions that then result in thrombosis. Other features of the design include (i) a flexible rotor and/or pump housing that can reduce blood damage, (ii) hydrophilic slippery coatings at high sheer components, such as the rotor to further reduce protein adsorption and thus thrombosis risk, (iii) magnetic-based drive and bearing components that can improve the hemocompatibility of the blood pump, and (iv) advanced controls and charging.
A61M 60/178 - Implantable pumps or pumping devices, i.e. the blood being pumped inside the patient’s body implantable in, on, or around the heart drawing blood from a ventricle and returning the blood to the arterial system via a cannula external to the ventricle, e.g. left or right ventricular assist devices
A61M 60/216 - Non-positive displacement blood pumps including a rotating member acting on the blood, e.g. impeller
A61M 60/861 - Connections or anchorings for connecting or anchoring pumps or pumping devices to parts of the patient’s body
17.
COMPOSITIONS AND METHODS FOR PURIFYING VIRAL VECTORS
The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production and purification of adeno-associated viruses (AAVs).
Disclosed herein are thrombin-sensitive platelet like particles. The particles can be used to promote healing in a variety of wounds and can be used in drug delivery systems.
A61L 26/00 - Chemical aspects of, or use of materials for, liquid bandages
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C08L 33/26 - Homopolymers or copolymers of acrylamide or methacrylamide
A transparent structure (40) for emitting light is described. The transparent structure comprises an emissive layer (EML) (44) positioned between first (46) and second (42) electrodes. The EML (44) is tuned such that luminance through the first electrode (46) is greater than luminance through the second electrode (42).
In one aspect, the disclosure relates to a method for removing a hyperpolarization catalyst from a solution comprising a hyperpolarized molecule, the method including at least the step of filtering the solution using a silica-based sorbent such as a normal phase, reverse phase, or ion exchange silica-based sorbent. In an aspect, the hyperpolarization catalyst includes a metal center such as Ir, Rh, Co, Fe, Ru, Pd, or Ni. In any of these aspects, the hyperpolarized molecule includes at least one hyperpolarized nucleus selected from 1H, 15N, 13C, or a combination thereof, wherein the nucleus has been hyperpolarized using signal amplification by reversible exchange. In another aspect, the filtration step separates the hyperpolarization catalyst from the hyperpolarized molecule based on at least one differing property. Also disclosed are biocompatible contrast agents containing the hyperpolarized molecules and methods of imaging using the same.
B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01J 8/00 - Chemical or physical processes in general, conducted in the presence of fluids and solid particlesApparatus for such processes
21.
MAGNETIC FIELD CONTROL OF SABRE HYPERPOLARIZED MOLECULES FOR PROCESSING AND ADMINISTRATION
In one aspect, the disclosure relates to a method for conserving hyperpolarization in a hyperpolarized molecule undergoing at least one processing step, the method including conducting the at least one processing step in a magnetic field having a magnetic field strength higher than the magnetic field strength of Earth. In an aspect, prior to the at least one processing step but following hyperpolarization, the molecule can be transferred into a processing magnetic field in an adiabatic manner. In still another aspect, following the processing step, the molecule can be transferred into a signal detection magnetic field in an adiabatic manner. Prior to performing the method, the hyperpolarized molecule can be produced using signal amplification by reversible exchange (SABRE). Also disclosed herein are hyperpolarized molecules prepared by the disclosed methods, contrast agents comprising the same, and methods for diagnosing a disease or monitoring the progress of disease treatment using the same.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
G01R 33/28 - Details of apparatus provided for in groups
G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
22.
PORTABLE DEVICE FOR ENUMERATION AND SPECIATION OF FOOD ANIMAL PARASITES
A device can automatically count, speciate, and determine infectivity of eggs of parasites in food animals. The device can include a chamber that can receive a sample specimen. Additionally, the device can include a light source. The light source can illuminate a field of view of the sample specimen in the chamber. The device can further include a microscope objective to magnify the field of view of the sample specimen. The device can include a camera. The camera can image the field of view of the sample specimen. The camera can further produce an on-site dataset of images. Additionally, the camera can provide the on-site dataset of images to a trained machine-learning model for analysis of at least one species of parasites.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing
The present disclosure provides compositions and methods related to aptamer-based sensors. In particular, the present disclosure provides aptamer-based sensors, and related detection assays, that are capable of binding fentanyl (and derivatives and analogs thereof) at nanomolar concentrations in biological samples in a manner that is rapid and specific.
The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides compositions, and related methods, comprising peptide ligands capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production and purification of adeno-associated viruses (AAVs).
e.g.e.g.e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production of a biologic.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
C07K 5/11 - Tetrapeptides the side chain of the first amino acid containing more amino groups than carboxyl groups, or derivatives thereof, e.g. Lys, Arg
C07K 5/113 - Tetrapeptides the side chain of the first amino acid containing more carboxyl groups than amino groups, or derivatives thereof, e.g. Asp, Glu, Asn
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
26.
COMPOSITIONS AND METHODS RELATING TO INHALABLE THERAPEUTIC COMPOSITIONS
The present disclosure provides compositions and methods related to inhalable therapeutics. In particular, the present disclosure provides hydrogel-based inhalable bioadhesives that safely and effectively coat the airway to provide a barrier against pathogenic organisms, allergens, and environmental pollutants.
The present disclosure provides compositions and methods related to multiparatopic aptamers. In particular, the present disclosure provides nucleic acid aptamers capable of binding multiple distinct epitopes on a target biomolecule, as well as corresponding methods of generating and characterizing the multiparatopic aptamers.
Various examples are provided related to electrocardiogram (ECG) monitoring from inertial measurement unit (IMU) signals. In one example, a method includes obtaining seismocardiogram (SGD) signals from IMU attached to a canine, the SGD signals including a first subset of signals generated by the IMU prior to a target timestamp and a second subset of signals generated by the IMU after the target timestamp; extracting input features from the SGD signals; and generating reconstructed ECG signals from the extracted input features using at least one neural network, where the reconstructed ECG signals represent an ECG reading of the canine. In another example, a system includes one or more IMU that can provide SGD signals and processing circuitry that can receive SGD signals from the one or more IMU; extract input features from the SGD signals; and generate reconstructed ECG signals from the extracted input features.
Disclosed herein are methods for graft polymerizing cationic alkenyl monomers, or polymers made therefrom, into undyed or dyed cellulosic materials. Further provided are methods for dyeing such cationized cellulosic materials, and to dyed or undyed cationized cellulosic materials prepared by the disclosed methods.
Various examples are provided related to superfluorescence (SF) at room temperature. In one example, an upconversion nanoparticle (UCNP) includes a nanocrystal lattice doped with a rare earth element, the rare earth element distributed in the nanocrystal lattice with a coupling distance that produces anti-Stokes shifted SF. The rare earth element can be a Nd3+ ion.
G02F 1/1523 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulatingNon-linear optics for the control of the intensity, phase, polarisation or colour based on an electrochromic effect characterised by the electrochromic material, e.g. by the electrodeposited material comprising inorganic material
B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
B82Y 40/00 - Manufacture or treatment of nanostructures
B82Y 99/00 - Subject matter not provided for in other groups of this subclass
31.
BI-DIRECTIONAL FIELD EFFECT TRANSISTOR (BIDFET)-BASED AC-DC POWER CONVERTER
Various examples are provided related to AC-DC power conversion. In one example, a power converter includes a first bridge circuit including a plurality of bidirectional field effect transistor (BiDFET) devices; a second bridge circuit; a link coupling the first and second bridge circuits; and control circuitry to control operation of the plurality of BiDFET devices of the first bridge circuit and switching devices of the second bridge circuit. The control circuitry includes a gate-driver to provide isolated driving signals to each BiDFET device that cause continuous conductance of a first switch of the BiDFET device though a corresponding switching period and modulates a second switch of the BiDFET device through the corresponding switching period.
H02M 7/86 - Conversion of AC power input into DC power outputConversion of DC power input into AC power output with possibility of reversal by dynamic converters
H02M 3/335 - Conversion of DC power input into DC power output with intermediate conversion into AC by static converters using discharge tubes with control electrode or semiconductor devices with control electrode to produce the intermediate AC using devices of a triode or a transistor type requiring continuous application of a control signal using semiconductor devices only
H03K 17/687 - Electronic switching or gating, i.e. not by contact-making and -breaking characterised by the use of specified components by the use, as active elements, of semiconductor devices the devices being field-effect transistors
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
Inventor
Brudno, Yevgeny
Vanblunk, Madelyn
Pandit, Sharda
Agarwalla, Pritha
Dotti, Gianpietro
Abstract
The present disclosure provides compositions, systems, and methods related to cellular transduction. In particular, the present disclosure provides compositions, systems, and methods pertaining to implantable macroporous scaffolds that facilitate rapid and highly efficient cellular transduction.
The present disclosure provides compositions and methods related to the purification and/or isolation of antibodies. In particular, the present disclosure provides novel peptide ligands capable of targeting the fragment antigen binding (Fab) domain and/or single-chain variable fragment (scFv) of antibodies to facilitate the isolation and/or purification of antibodies from processing fluid streams. The novel ligands disclosed herein are capable of universal and subtype-specific biorecognition.
Disclosed herein are systems and methods related to the construction of solid structures. In various implementations, the structures are formed by obtaining a flexible mold having a first membrane defining a first surface and a second surface, and a second membrane defining a third surface and a fourth surface. The first surface at least partially defines a first volume, and the second surface at least partially defines a second volume. The flexible mold further defines at least one inlet port in fluid communication with the first volume. A fluidic building material flows through the at least one inlet port into the first volume of the flexible mold, and an inflation fluid flows into the second volume of the flexible mold to expand the second volume of the flexible mold. The fluidic building material can then change from a fluid to a solid structure.
E04B 1/16 - Structures made from masses, e.g. concrete, cast or similarly formed in situ with or without making use of additional elements, such as permanent forms, sub-structures to be coated with load-bearing material
E04H 15/22 - Tents or canopies, in general inflatable, e.g. shaped, strengthened or supported by fluid pressure supported by air pressure inside the tent
35.
COMPOSITIONS AND METHODS RELATED TO EXOSOMAL DELIVERY OF THERAPEUTIC AGENTS
The present disclosure provides compositions and methods related to engineered extracellular vesicles (EVs). In particular, the present disclosure provides a novel exosome-specific delivery scaffold for administering therapeutic agents to a subject. The exosome-specific scaffold can be used to generate and deliver EVs containing biologically active cargo (e.g., mRNA, tumor antigens, small molecule drugs) to a subject to treat and/or prevent disease (e.g., viral infection, cancer, etc.).
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
36.
ENGINEERED MICROORGANISMS WITH ENHANCED PROTEIN EXPRESSION AND SECRETION
The present disclosure provides materials and methods related to the production of peptides and polypeptides from engineered microorganisms. In particular, the present disclosure provides compositions and methods for producing a genetically modified microorganism (e.g., yeast cell) with enhanced protein expression and/or secretion.
Various examples are provided related to reservoir computing. In one example, a physical reservoir computer includes processing circuitry having an input layer; a reservoir comprising a forced limit-cycle oscillator, the reservoir implemented without delay or feedback; and a readout layer. The forced limit-cycle oscillator can include a Hopf oscillator or a Lorenz oscillator. The processing circuitry can include analog processing circuitry, optoelectronic circuitry, or other appropriate processing circuitry.
A process for preparing conversion-ready feedstock (CRF) is described. The process can be used to convert municipal solid waste (MSW) into CRF for the preparation of biochemicals, biofuels, biopower, and bioproducts. An exemplary process involves extruding MSW to provide a mechanically homogenized material that can be further processed prior to, during, or after extrusion (or another mechanical homogenization treatment) to provide the CRF. Also described are a system for preparing CRF from MSW and exemplary CRF made from converted MSW.
In one aspect, the disclosure relates to precipitated hyperpolarized substrates, methods of making the same, contrast agents comprising the same, and methods of diagnosing and/or monitoring the progress of a disease using the same. In one aspect, the method comprises contacting a solution containing a first solvent and a hyperpolarized substrate with a non-polar organic solvent. In a further aspect, the precipitated hyperpolarized substrate can be separated from the first solvent, the non-polar organic solvent, or any combination thereof by filtration. In still another aspect, the method further includes redissolving the precipitated hyperpolarized substrate in a biocompatible solvent such as, for example, water or a physiologically-acceptable buffer. In any of these aspects, hyperpolarization of the substrate can be accomplished using Signal Amplification by Reversible Exchange (SABRE).
The present disclosure provides compositions, methods, devices, and systems related to biomass composting and carbon dioxide capture. In particular, the present disclosure provides compositions, methods, devices, and systems for the production of high purity carbon dioxide from a wide variety of biomass feedstock in a more efficient and cost-effective manner than conventional technologies.
B01D 53/14 - Separation of gases or vapoursRecovering vapours of volatile solvents from gasesChemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 53/34 - Chemical or biological purification of waste gases
41.
INTRAVASCULAR DUAL FREQUENCY SONOTHROMBOLYSIS MEDIATED WITH MICROBUBBLES/NANODROPLETS
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Jiang, Xiaoning
Xu, Zhen
Zhang, Bohua
Wu, Huaiyu
Kim, Jinwook
Kim, Howuk
Dayton, Paul, Alexander
Goel, Leela
Abstract
A method for sonothrombolysis mediated with contrast agents includes administering at least one contrast agent into a blood vessel of a patient. The method further includes controlling application of ultrasound energy to the at least one contrast agent within the blood vessel, wherein controlling the application of the ultrasound energy includes driving an ultrasound transducer with a signal having a first frequency component and a second frequency component different from the first frequency component.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
Various examples are provided related to methods and systems to reconstruct 3D image/map for the stiffness of soft tissues. In one example, a method includes obtaining particle velocities from generated mechanical waves in tissue of a subject; reconstructing a stiffness map of soft tissue in a region of interest (ROI) from the particle velocities; and generating an image of the stiffness map for rendering on a user device. In another example, a system includes an ultrasound scanner for shear wave elastography (SWE) and a computing or processing device that can obtain particle velocities; reconstruct a stiffness map of soft tissue in a ROI from the particle velocities; and generate an image of the stiffness map for rendering. The particle velocities can be generated from acoustic radiation forces produced by the ultrasound scanner.
C07C 51/56 - Preparation of carboxylic acid anhydrides from organic acids, their salts, or their esters
C07C 51/14 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reaction with carbon monoxide on a carbon-to-carbon unsaturated bond in organic compounds
C07C 67/38 - Preparation of carboxylic acid esters by reaction with carbon monoxide or formates by addition to an unsaturated carbon-to-carbon bond
B01J 31/28 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of the platinum group metals, iron group metals or copper
The invention relates to textile fibres, and particularly, although not exclusively, to textile microfibres and/or textile nanofibres, and their conversion into carbon nanomaterials. The invention extends to methods for converting non-biodegradable textile micro- and nanofibres and micro- and nanoplastics into harmless, non-toxic and/or biodegradable/biocompatible end-products, and encompasses apparatus and/or reactors used to perform these methods.
A01N 35/02 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having two bonds to hetero atoms with at the most one bond to halogen, e.g. aldehyde radical containing aliphatically bound aldehyde or keto groups, or thio-analogues thereofDerivatives thereof, e.g. acetals
This invention relates to recombinant nucleic acid constructs encoding Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and transposon 7-like (Tn7-like) transposon systems for DNA integration, as well as methods of using the same.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventor
Roy, Tuhin
Guddati, Murthy
Urban, Matthew W.
Capron, Charles B.
Abstract
Various examples are provided related to estimation of viscoelasticity of an arterial or venous wall. In one example, a method includes obtaining ultrasound data of an arterial or venous wall for a defined acoustic radiation force; and determining viscoelasticity of the arterial or venous wall. The viscoelasticity can be determined based upon correlation between measured and simulated wall velocity of the ultrasound data in a space-time, a wavenumber-frequency, wavenumber-time, or space-frequency domain; or in a sequential manner by determining the elastic part of the modulus by matching measured and simulated phase velocities and determining the viscoelasticity part by matching measured and simulated wall velocities; or a combination of both. The simulated velocity can be determined for a wall thickness and viscoelastic modulus of the arterial or venous wall through full wave analysis. In another example, a system includes an ultrasound scanner and a computing device that can implement the method.
The present invention provides novel redox catalysts and processes using the redox catalyst for the oxidative dehydrogenation of alkylaromatics. The catalyst enables the dehydrogenation reaction to produce an alkenylaromatic and hydrogen, the selective hydrogen combustion reaction of lattice oxygen with the hydrogen to produce steam, and carbon monoxide/dioxide (COX) management by mitigating COX production, capturing the COx, and/or or otherwise providing COX resistance.
B01J 23/00 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group
C07C 5/48 - Preparation of hydrocarbons from hydrocarbons containing the same number of carbon atoms by dehydrogenation with a hydrogen acceptor with oxygen as an acceptor
50.
METHOD TO REDUCE HUMAN EXERTION DURING WALKING WITHOUT AFFECTING GAIT KINEMATICS
Various examples are provided related to gait kinematics. A methodology for human in the loop optimization (HILO) for use of a hip exoskeleton is presented. In one example, a method includes monitoring a gait phase of an exoskeleton and controlling switching time between admittance parameters associated with actuator control of the exoskeleton, where the switching time is controlled based upon the monitored gait phase. The admittance parameters can be predetermined and can be user specific. The time of the switching can be determined from use of the exoskeleton and can be determined using reinforcement learning.
Methods of preparing melt-spun polyacrylonitrile (PAN) fibers are described. The fibers can be used as carbon fiber precursors and/or carbonized and graphitized to provide carbon fibers. The methods can include melt-spinning mixtures of PAN and a meltable solvent, such as dimethyl sulfone. In some methods, the mixtures also include lignin and/or can include waste PAN or PAN copolymers prepared from bio-derived monomers. Carbon fibers and carbon fiber composites prepared from the melt-spun fibers are also described.
D01D 5/10 - Melt-spinning methods using organic materials
D01F 9/17 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments from products of vegetable origin or derivatives thereof, e.g. from cellulose acetat from lignin
D01F 9/22 - Carbon filamentsApparatus specially adapted for the manufacture thereof by decomposition of organic filaments from polyaddition, polycondensation or polymerisation products from macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds from polyacrylonitriles
D01F 8/08 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the likeManufacture thereof from synthetic polymers with at least one polyacrylonitrile as constituent
52.
SIMULTANEOUS MULTIPLEX SCREENING FOR DETECTION OF SUBSTITUTION VARIANTS AND INDELS WITHIN NUCLEOTIDE SEQUENCES
Provided are methods for simultaneously determining genotypes of a subject with respect to two or more loci of interest, at least one first locus of interest of which is characterized, by alleles that differ from each other with respect to a nucleotide substitution and at least one second locus of interest of which is characterized by alleles that differ from each other with respect to the presence or absence of an indel. In some embodiments, the methods include using pluralities of amplification primer sets that, are designed to product amplification fragments indicative of the various genotypes such that each some or all of the genotypes can be simultaneously identified using a single size-based separation technique and/or other detection technique. The presently disclosed subject matter also provides kits for use in the presently disclosed methods and methods for differentially treating subjects with diseases, disorders, and/or condition associated with undesirable gene expression based on the genotypes of the subject identified with the presently disclosed approaches.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Sustainable paper-based packaging materials, e.g., packaging materials comprising agro-based microfibrillated cellulose (A-MFC), are described. The packaging materials include coatings and films prepared from A-MFC derived from hemp hurds, cocoa pod husks, and other agro-residues or byproducts and having a high level of primary and/or secondary fines. Methods of preparing the A-MFC can involve a reduced amount of energy compared to wood-derived materials and the packaging materials can have enhanced barrier and mechanical properties, such as enhanced oil and grease resistance.
Provided are methods for detecting urogenital malignancies in dogs. In some embodiments, the methods include identifying a deletion or single nucleotide substitution within a BRAF gene and/or within a MAP2K1 gene present in or isolated from a biological sample from a. dog, wherein the presence of the deletion or single nucleotide substitution within the BRAF gene and/or within the MAP2K1 gene detects a urogenital malignancy, optionally transitional cell carcinorna/urothelial carcinoma, in the dog. In some embodiments, the deletion is within exon 12 of BRAF gene, optionally within the amino acid sequence KMLNVTAPTPQQL (SEQ ID NO: 3), and/or in within exon 2 or 3 of a M.AP2K1 gene, optionally within the amino acid sequence FLTQKQKVGE (SEQ ID NO: 4).
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present disclosure provides materials and methods related to the production of peptides and polypeptides from engineered microorganisms. In particular, the present disclosure provides compositions and methods for producing a genetically modified microorganism (e.g., yeast cell) with enhanced protein expression and/or secretion.
The present invention relates to vortex ultrasound transducers and methods of therapeutic ultrasound treatment. A device for therapeutic ultrasound treatment includes a jacket for insertion within a blood vessel of a patient and an ultrasound transducer located within the jacket and comprising a plurality of active elements that are arranged such that, when activated, the ultrasound transducer is configured to generate ultrasound energy with a swirling movement that produces a mechanical shear stress over a target area within the blood vessel of the patient.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
G10K 11/34 - Sound-focusing or directing, e.g. scanning using electrical steering of transducer arrays, e.g. beam steering
57.
METHOD FOR PROTON-ONLY DETECTION OF HYPERPOLARIZED HETERONUCLEAR SINGLET STATES
In one aspect, the disclosure relates to a method for hyperpolarizing the long-lived singlet state of 1322 pyruvate with parahydrogen and transferring the polarization to methyl pyruvate protons for detection, or to protons in other target analytes having a long-lived hyperpolarized singlet state and protons weakly couple into the singlet spin pair. In a further aspect, the method can be conducted on conventional, proton-only MRI systems. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A hyperpolarization system including a solution and at least one magnetic field controller. The solution includes at least parahydrogen, a polarization transfer complex (PTC), and substrate molecules. The at least one magnetic field controller is configured to apply a static ultra-low magnetic field to the solution and apply an alternating ultra-low magnetic field to the solution. Through application of the ultra-low magnetic fields to the solution, the system hyperpolarizes at least some of the substrate molecules.
The present disclosure provides compositions and methods related to engineered extracellular vesicles (EVs). In particular, the present disclosure provides a novel delivery platform for administering therapeutic agents to a subject using engineered EVs. As provided herein, EVs can be used to deliver biologically active cargo (e.g., mRNA, tumor antigens, small molecule drugs) to a subject to treat and/or prevent disease (e.g., viral infection, cancer, etc.).
Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity. Compositions comprising these compounds, as well as methods of using thereof, are also described. For example, the compounds described herein can be used in human and animal health (e.g., for the treatment of infection), agriculture, marine coatings, and other coating applications related to prevention of biofilm (e.g., dental, medical, etc.).
Provided herein are compounds that can exhibit activity as biofilm modulating agents (e.g., activity as biofilm inhibitors and/or activity as biofilm dispersal agents). The compounds can exhibit potent activity against Gram positive biofilms. The compounds can also exhibit activity against Gram negative biofilms. In some cases, the compounds can exhibit both biofilm modulation properties and antimicrobial activity. Compositions comprising these compounds, as well as methods of using thereof, are also described. For example, the compounds described herein can be used in human and animal health (e.g., for the treatment of infection), agriculture, marine coatings, and other coating applications related to prevention of biofilm (e.g., dental, medical, etc.).
C07D 207/27 - 2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
C07D 207/30 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
Various examples are provided related to diversity based deep learning. In one example, a learned diversity neural network (LDNN) system includes an input layer; an output layer; and at least one hidden layer including at least one activation function neuronal network. The at least one activation function neuronal network includes an input node, an output node, and a plurality of intermediate nodes coupled between the input and output nodes and isolated from other nodes or other activation function neuronal networks of the at least one hidden layer.
A novel localized, mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing the efficacy of therapeutics and increasing immune cell infiltration. A miniaturized dual-lumen catheter device is configured to deliver M-HIFU to a tumor that does not have the anatomic limitations of conventional HIFU, and enables access to a primary or metastatic tumor regardless of the location.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A device for therapeutic ablative treatment of residual plaque on, in, and/or surrounding a stent within a blood vessel of a subject includes a jacket configured for insertion within a stent within a blood vessel of a subject. The device further includes an ultrasound transducer located within the jacket and having at least one active element oriented to deliver ultrasound energy in a radial and/or axial direction of the jacket from within the stent to ablate the residual plaque.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61F 2/86 - Stents in a form characterised by wire-like elementsStents in a form characterised by a net-like or mesh-like structure
65.
MELT SPINNING OF BLENDED CELLULOSE ACETATE BUTYRATE FIBERS
Methods of preparing fibers comprising cellulose esters are described. The fibers include bicomponent core-sheath fibers where the core comprises one or more cellulose esters and the sheath comprises a polyolefin prepared by co-extrusion of mixtures comprising a cellulose ester and mixtures comprising a polyolefin, as well as substantially solid body fibers prepared by melt-spinning a mixture comprising one or more cellulose ester and a meltable solvent. Also described are fibers comprising cellulose esters, e.g., the fibers prepared by the disclosed methods, and related articles, such as textiles, clothing, synthetic fibers, and faux fur. The fibers can include colorants (e.g., colorants derived from natural materials) and/or flame retardants.
D01F 8/02 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the likeManufacture thereof from cellulose, cellulose derivatives, or proteins
B29C 48/18 - Articles comprising two or more components, e.g. co-extruded layers the components being layers
B32B 27/12 - Layered products essentially comprising synthetic resin next to a fibrous or filamentary layer
Methods of preparing mono- and multi-component fibers comprising polylactic acid (PLA) are described. Exemplary fibers include co-extruded bicomponent core-sheath fibers where the core includes PLA and the sheath includes polyolefin. The fibers can include various colorants, such as colorants derived from natural materials and/or flame retardants. Also described are fibers comprising PLA, e.g., the fibers prepared by the disclosed methods, and related articles, such as textiles, clothing, synthetic fibers, and faux fur.
D01F 8/14 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the likeManufacture thereof from synthetic polymers with at least one polyester as constituent
D01F 8/16 - Conjugated, i.e. bi- or multicomponent, man-made filaments or the likeManufacture thereof from synthetic polymers with at least one other macromolecular compound obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
D04H 1/541 - Composite fibres e.g. sheath-core, sea-island or side-by-sideMixed fibres
D01F 1/07 - Addition of substances to the spinning solution or to the melt for making fire- or flame-proof filaments
B01J 19/24 - Stationary reactors without moving elements inside
B01J 19/12 - Processes employing the direct application of electric or wave energy, or particle radiationApparatus therefor employing electromagnetic waves
C01B 3/26 - Production of hydrogen or of gaseous mixtures containing hydrogen by decomposition of gaseous or liquid organic compounds of hydrocarbons using catalysts
68.
METHODS AND COMPOSITIONS FOR PRODUCING TOBACCO PLANTS WITH REDUCED NICOTINIC ALKALOID LEVELS
The present disclosure provides compositions and methods related to tobacco plants. In particular, the present disclosure provides novel methods for producing tobacco plants, and any related tobacco products, having low nicotinic alkaloid content. Tobacco plants produced according to the methods of the present disclosure exhibit reduced levels of nicotinic alkaloids (e.g., nicotine) compared to both naturally-occurring and transgenic tobacco plants, and thus represent a commercially valuable alternative to currently available tobacco varieties.
Disclosed herein is a novel Cas9 protein. Further described herein are fusion proteins, compositions, and methods comprising the same. The novel Cas9 protein may be used, for example, in compositions and methods for modulating expression of a gene, for correcting a mutant gene, and for treating a disease.
The present disclosure provides compositions and methods related to the culturing of trophoblast stem cells (TSCs). In particular, the present disclosure provides novel formulations and methods for inducing and maintaining trophoblast stem cells obtained from cytotrophoblasts (CTBs) obtained from a placenta at birth. The compositions and methods described herein allow for the development of in vitro models of early human placental development and establish a platform for therapeutic discoveries.
NMPOBBLBBL) genes to produce low-nicotine tobacco plants and which prevent the accumulation of anatabine in the tobacco plants. Also provided are methods of combining these mutations to produce tobacco plants, tobacco cells, and tobacco products having reduced nicotine content and which avoid the unwanted consequence of elevated anatabine levels in the tobacco plants, cells, and products.
A01H 6/82 - Solanaceae, e.g. pepper, tobacco, potato, tomato or eggplant
C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
C12Q 1/6895 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for plants, fungi or algae
Disclosed is mechanical and decolorization pretreatment of cotton-containing textiles, such as "trash" feedstock in terms of end-of-life-cotton textiles, that may be used to produce sugar without the use of harsh pretreatments conditions.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (USA)
Inventor
Dayton, Paul Alexander
Kim, Jinwook
Jiang, Xiaoning
Zhang, Bohua
Wu, Huaiyu
Xu, Zhen
Abstract
A method for disrupting a blood clot with ultrasound and at least one cavitation enhancing agent includes administering at least one cavitation enhancing agent into a blood vessel of a subject. The method further includes monitoring the at least one cavitation enhancing agent to determine when at least a portion of the at least one cavitation enhancing agent has reached a blood clot. The method further includes controlling application of ultrasound energy to the at least one cavitation enhancing agent within the blood vessel of the subject such that, during a first time period, cavitation-enhancing ultrasound energy is not applied to the at least one cavitation enhancing agent within the blood vessel and, during a second time period after the first time period, cavitation enhancing ultrasound energy is applied to the at least one cavitation enhancing agent within the blood vessel.
A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
75.
COMPOSITIONS AND METHODS RELATED TO A DUAL-AFFINITY RATIOMETRIC QUENCHING BIOASSAY FOR DETECTING GLYCOPROTEINS
The present disclosure provides compositions, methods, and systems related to a dual-affinity ratiometric quenching bioassay. In particular, the present disclosure provides novel compositions and methods that combine selective biorecognition and quenching of fluorescence signals for rapid and sensitive quantification of proteins in complex samples.
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 1/22 - Affinity chromatography or related techniques based upon selective absorption processes
76.
MODIFIED ALGINATES AND METHODS OF MAKING AND USING THEREOF
The loss of cross-linking abilities in highly substituted alginate scaffolds is a significant problem affecting the use of alginate polymers in implants, cell delivery, and tissue engineering. Disclosed are modified alginate scaffolds that retain their gelation properties under high chemical modification, as well as methods of making and using thereof.
An implantable device is provided that includes a tubular body with at least one open end, defining an inner space, a cap closing the at least one open end and having an inner surface on one side and an outer surface on the other side, the inner surface facing the inner space, and a circuit board being placed in the inner space, having an active surface, a board electrode disposed on the active surface, and a wireless communication circuit to communicate outside of a body, biological information obtained via the board electrode. Moreover, a recess and an inner electrode are disposed on the inner surface of the cap, and the circuit board is disposed in the recess, and the inner electrode is electrically connected to the board electrode. An outer electrode is disposed on the outer surface of the cap and is electrically connected to the inner electrode.
Provided according to embodiments of the invention are methods of forming an amino-functionalized compounds by hydroaminomethylation. Methods include the steps of hydroformylating an alkene (or alkyne) to produce an aldehyde; condensing the aldehyde with an amine reactant to produce an imine, iminium ion, and/or an enamine; and optionally hydrogenating the imine, iminium ion, and/or an enamine to form the amino-functionalized compound, wherein at least one of method steps is performed in the presence of a bidentate diphosphorous ligand, an acid, and at least one of a rhodium (I) metal, a rhodium (I) compound and a salt thereof. Related compositions are also provided.
C07C 209/60 - Preparation of compounds containing amino groups bound to a carbon skeleton by condensation or addition reactions, e.g. Mannich reaction, addition of ammonia or amines to alkenes or to alkynes or addition of compounds containing an active hydrogen atom to Schiff's bases, quinone imines, or aziranes
C07C 209/66 - Preparation of compounds containing amino groups bound to a carbon skeleton from or via metallo-organic compounds
C07C 209/68 - Preparation of compounds containing amino groups bound to a carbon skeleton from amines, by reactions not involving amino groups, e.g. reduction of unsaturated amines, aromatisation, or substitution of the carbon skeleton
79.
COMPOSITIONS AND METHODS FOR PURIFYING BIOLOGICAL FLUIDS
e.g.e.g.e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from biological fluids during the production of a biologic.
This invention is directed to recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and recombinant nucleic acid constructs encoding clostridia Type I-B CASCADE complexes, expression cassettes and vectors comprising the same, and methods of use thereof for modifying genomes, altering expression, killing one or more cells in a population of cells, and screening or selecting for genomic variants of an organism.
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
NORTH CAROLINA STATE UNIVERSITY (USA)
BLATEK INDUSTRIES, INC. (USA)
Inventor
Chen, Qiyang
Sheng, Zhiyu
Zhang, Bohua
Kim, Howuk
Wu, Huaiyu
Jiang, Xiaoning
Chen, Mengyue
Geng, Xuecang
Abstract
Ultrasound systems and methods of use are provided for rapidly heating a target area of a subject. The ultrasound system can include at least one imaging transducer array for imaging the target area, and at least two spaced-apart heating transducer arrays for heating the target area. The at least two heating transducer arrays can be separated by the at least one imaging transducer array on an ultrasound probe.
This invention relates to methods for increasing phage resistance in Clostridium species through incorporation of novel recombinant Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) RNAs using endogenous CRISPR systems and/or recombinant nucleic acid constructs encoding clostridia Type I-B and Type I-C CASCADE complexes, and/or expression cassettes and vectors comprising the same.
Provided are expression cassettes that can be used to express proteins in plants. In some embodiments, the expression cassettes include polynucleotides that encode polypeptides that are at least 96% identical to SEQ ID NO: 2 operably linked to a promoter and a transcription terminator and optionally a tag sequence. Also provided are recombinant vectors, cells, and transgenic plants, progeny, and seeds that include the presently disclosed expression cassettes, and methods for using the disclosed expression cassettes to alter geminivirus resistance and suppress virus-induced leaf chlorosis, leaf curling, or both in plants.
The disclosure relates to nonwoven fabric including a nonwoven material having a first surface and an opposing second surface, wherein the first surface has a first average surface charge and the second surface has a second average surface charge, the first average surface charge being different from the second average surface charge, wherein the nonwoven material includes a first plurality of fibers including a first polymer and a second plurality of fibers including a second polymer different from the first polymer. A method for imparting surface charge to a nonwoven fabric is also provided.
D06M 10/00 - Physical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. ultrasonic, corona discharge, irradiation, electric currents or magnetic fieldsPhysical treatment combined with treatment with chemical compounds or elements
The present disclosure provides compositions and methods related to nucleic acid molecules having therapeutic activity. In particular, the present disclosure provides nucleic acid molecules comprising one or more aptamers having anticoagulant activity, as well as corresponding antidote nucleic acid molecules capable of modulating anticoagulant activity.
BOARD OF TRUSTEES OF SOUTHERN ILLINOIS UNIVERSITY (USA)
NATIONAL INSTITUTES OF HEALTH, NHLBI (USA)
Inventor
Theis, Thomas
Chekmenev, Eduard, Y.
Goodson, Boyd
Ettedgui, Jessica
Adelabu, Isaiah
Kabir, Mohammad
Nantogma, Shiraz
Abdulmojeed, Mustapha
Lehmkuhl, Sören
Tomhon, Patrick
Mandzhieva, Iuliia
Swenson, Rolf, Eric
Abstract
In one aspect, the disclosure relates to hyperpolarized target molecules and contrast agents comprising the same, methods of making the same, and methods of imaging using same. In a further aspect, imaging performed using the hyperpolarized target molecules and contrast agent can enable real time monitoring and diagnosis of diseases including various cancers and metabolic disorders. The methods are cryogen-free and inexpensive and can be performed in a short time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
The present disclosure provides compositions, methods, and kits related to DNA transformation in bacteria. In particular, the present disclosure provides novel compositions and methods for enhancing DNA transformation by replicating a DNA methylation pattern used in a bacterial host strain. The compositions, methods, and systems described herein utilize cell-free transcription-translation mixtures and DNA methylation complexes to increase transformation efficiency and efficacy for any bacterial host.
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
88.
HYDROFORMYLATION PROCESS FOR PREPARING LINEAR AND BRANCHED ALDEHYDES
Described are processes for preparing linear and branched aldehydes, which comprises reacting an olefin with hydrogen and carbon monoxide in the presence of a catalyst solution comprising rhodium, a hydroformylation solvent, and a fluorophosphite ligand having the general formula (I).
C07C 45/50 - Preparation of compounds having C=O groups bound only to carbon or hydrogen atomsPreparation of chelates of such compounds by reaction with carbon monoxide by oxo-reactions
B01J 27/185 - PhosphorusCompounds thereof with iron group metals or platinum group metals
HELMHOLTZ-ZENTRUM BERLIN FÜR MATERIALIEN UND ENERGIE GMBH (Germany)
Inventor
Luiso, Salvatore
Fedkiw, Peter S.
Spontak, Richard John
Quan, Ting
Lu, Yan
Abstract
The disclosure relates to a gel polymer electrolyte (GPE) for use with an electrochemical cell, e.g., a lithium ion battery. The GPE comprises a polymer matrix containing a sulfonated block copolymer and water in salt electrolyte (WiSE). The GPE is characterized as being stable in an electrochemical cell environment, with enhanced ionic conductivity and ionic barrier properties. the WiSE is a metal salt having a salt concentration above saturation point. The polymer matrix is characterized as having an ion exchange capacity (IEC) of at least 0.5 meg/g.
Sustainable paper-based packaging materials, e.g., paper-based food packaging materials, are described. The packaging materials are based on paper formed from fiber derived from waste biomass, such as hemp hurds, mixes containing hemp hurds and hemp bast fibers, bagasse, and cocoa pod husks. Also described are methods of making the packaging materials. The methods can include environmentally friendly pulping and/or bleaching processes.
D21H 11/18 - Highly hydrated, swollen or fibrillatable fibres
D21H 21/14 - Non-fibrous material added to the pulp, characterised by its function, form or propertiesPaper impregnating or coating material, characterised by its function, form or properties characterised by function or properties in or on the paper
91.
COMPOSITIONS AND METHODS RELATED TO THE TREATMENT OF OCULAR DISEASES IN EQUINES
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
Inventor
Gilger, Brian
Crabtree, Elizabeth
Hirsch, Matthew L.
Abstract
The present disclosure provides compositions and methods related to the treatment of ocular diseases in equines. In particular, the present disclosure provides novel compositions and methods related to the administration of therapeutic compositions comprising AAV-equine IL-10 for the treatment and/or prevention of various ocular diseases (e.g., non-infectious uveitis).
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
92.
TEXTILE GAS-LIQUID-SOLID CONTACTORS AND BIOCATALYTIC MATERIALS AND METHODS COMPRISING SAME
In various exemplary embodiments, the present disclosure provides novel water¬ absorbent textile-based gas-liquid-solid contactors for carbon dioxide (CO2) gas separation, as well as novel methods for producing and using these materials. The water-absorbent textile-based contactors of the present invention allow aqueous liquids to penetrate and travel intimately throughout the water-absorbent textile structure. The textile structure comprises many fibers with small diameters which creates a very high surface area. When exposed to a gas, the gas will be in contact with liquid spread throughout the solid wetted textile structure, all three phases "gas-liquid-solid" are in intimate contact. The textile contactor itself has superior performance compared to conventional packing materials, and, when combined with biocatalysts, the performance improves even more dramatically. By incorporating a biocatalyst, the invention enables use of benign solvents that have otherwise been overlooked in conventional systems due to poor kinetics.
D03D 15/47 - Woven fabrics characterised by the material, structure or properties of the fibres, filaments, yarns, threads or other warp or weft elements used characterised by the structure of the yarns or threads multicomponent, e.g. blended yarns or threads
D06M 16/00 - Biochemical treatment of fibres, threads, yarns, fabrics or fibrous goods made from such materials, e.g. enzymatic
Disclosed herein are recombinant meganucleases engineered to bind and cleave a recognition sequence in the mitochondrial DNA (mtDNA) of a eukaryotic cell, such as a plant cell. The disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells, and to a population of genetically-modified eukaryotic cells wherein the mtDNA has been having modified or edited.
Described herein are compounds that include a first porphyrin; and a first hydroporphyrin, wherein the first porphyrin is attached to the first hydroporphyrin. The compound may be a luminescent compound (e.g., a fluorescent compound). Also provided are particles and compositions including compounds described herein. Further provided are methods of making and using the particles and methods of making the same.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
95.
RECOMBINANT VIRAL EXPRESSION VECTORS AND METHODS OF USE
The present disclosure provides materials and methods relating to recombinant viral expression vectors. In particular, the present disclosure provides novel recombinant viral expression vectors comprising an RNA virus backbone that encodes a virus capable of infecting a target organism and expressing a polynucleotide-of-interest in that target organism. The novel viral vector constructs provided herein are a versatile expression tool for interrogating gene function and an efficient delivery platform for gene editing technology.
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
NORTH CAROLINA STATE UNIVERSITY (USA)
Inventor
Hirsh, Matthew, Louis
Song, Liujiang
Gilger, Brian, Christopher
Abstract
e.g.e.g., cornea) of a subject and methods of using the same for treatment and prevention of corneal clouding and blindness in a subject due to mucopolysaccharidosis VI (MPS-VI) and other MPS VI-associated manifestations in the eye.
Methods and systems for quantum information processing. In some examples, a system for producing a superfluorescence photon source includes thin films of hybrid and lead halide containing perovskites under laser excitation. A system for producing superfluorescence photon sources can include one or more thin films of hybrid and lead halide containing perovskites and a laser excitation source configured for placing the one or more thin films under laser excitation.
Exemplary catalysts may comprise a two-dimensional substrate and at least one organometallic compound bonded to the two-dimensional substrate. The at least one organometallic compound may comprise a carbonyl group. Exemplary methods of preparing a polymer product may comprise combining a catalyst with an alcohol and an ester in a solvent, thereby generating a mixture, and obtaining the polymer product from the mixture.
The present disclosure provides compositions and methods relating to the use of stents treated with therapeutic biologics for the treatment of cardiovascular diseases and conditions. In particular, the present disclosure provides novel compositions and methods for conjugating therapeutic extracellular vesicles to a stent to not only regulate vascular remodeling and inflammation, but also promote the regeneration of the injured tissue.
Various examples are provided related to virtual performance compatibility checking and management for modular construction. In one example, a method includes segmenting boundaries of as-built and as-planned models of a construction element; determining features of each boundary segment of the as-built and as-planned models; determining similarity ratios for matching pairs of boundary segments of the as-built and as-planned models; comparing a total similarity ratio based upon the similarity ratios for matching pairs of boundary segments with a specified threshold; and snapping the as-built model in positionin a point cloud in response to the comparison. A system comprising computing or processing circuitry can execute a program or application to implement the similarity/compatibility checking methodology. The similarity/compatibility checking methodology can be implemented within a construction performance modeling and simulation (CPMS) framework.
patents
